Can Pharmacogenetic Variants in TPMT, MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?

导出 OA

翻译打印收藏纠错

第一作者： Marina,Jelovac

第一单位： Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia.

作者： Marina,Jelovac ^[1] ; Nikola,Kotur ^[1] ; Bojan,Ristivojevic ^[1] ; Djordje,Pavlovic ^[1] ; Vesna,Spasovski ^[1] ; Nemanja,Damjanov ^[2] ; Sonja,Pavlovic ^[1] ; Branka,Zukic ^[1]

作者单位： Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia. ^[1] Institute of Rheumatology, 11000 Belgrade, Serbia.;Medical School, University of Belgrade, 11000 Belgrade, Serbia. ^[2]

关键词 azathioprine methotrexate personalized therapy pharmacogenetics markers rheumatologic diseases systemic sclerosis

主题词人类(Humans);基因型(Genotype);硫唑嘌呤(Azathioprine);甲氨蝶呤(Methotrexate);硬皮病, 系统性(Scleroderma, Systemic);多态性, 单核苷酸(Polymorphism, Single Nucleotide);亚甲基四氢叶酸还原酶(NADPH)(Methylenetetrahydrofolate Reductase (NADPH2))

DOI 10.3390/ijms24108538

PMID 37239884

发布时间 2023-05-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交